Posts Tagged ‘Soft Tissue Sarcoma’
DAMASCUS, Md. – May 28, 2020 – The Sarcoma Foundation of America (SFA), an organization dedicated to increasing research and awareness for sarcoma, today announced that it has awarded three-quarters of a million dollars in research funds to deserving scientists as part of its 2020 SFA Research Grant program. Fifteen research grants, each worth $50,000, have been awarded to researchers who have made it their mission to study sarcoma, a cancer that arises in the body’s soft tissue and bone. All proposals are peer reviewed by members of the SFA Medical Advisory Board who award the grants to the best,… Read More »
Sarcoma is a rare type of cancer and typically produces malignant tumors derived from the connective tissue. There are more than 70 sarcoma types and subtypes. Soft Tissue Sarcoma Soft tissue sarcoma broadly defines cancers that develop in the body’s soft tissues (i.e. muscles, tendons, fat, lymph vessels, blood vessels, and nerves). While these cancers are most commonly found in the head, neck, arms, legs, chest, and abdomen, they can develop anywhere in the body. There are various different types of soft tissue sarcoma, and depending on the type of soft tissue the cancer started in, the cells will look… Read More »
Kenneth Cardona, MD, FACS, Associate Professor of Surgery, Winship Cancer Institute at Emory University Race to Cure Sarcoma™ Atlanta What inspired you to specialize in sarcoma? The rarity and complexity of this disease in combination with our limited treatment options outside of surgical therapy inspired me to focus my advanced surgical training in surgical oncology on this unique disease. What is the focus of the research performed in your lab? I am the lead and principal investigator of the Unites States Sarcoma Collaborative, which is a multi-institutional research effort amongst 8 academic institutions across the US studying this rare… Read More »
William K. Decker, PhD, Associate Professor, Baylor College of Medicine 2016 Pittsburgh Cure Sarcoma Co-Founder Carl Firetto Memorial Research Award: “Outbred Canine Model of Adjuvant Immunotherapy for Angiosarcoma” PLEASE DESCRIBE THE FOCUS OF THE RESEARCH PERFORMED IN YOUR LAB. We study the basic immunobiology of dendritic cells and the manner by which this critical cell subtype orchestrates TH polarization. TH polarization sounds complicated – and it is – but can be explained relatively easily. The adaptive immune system makes two main types of fundamentally different immune responses. One of these responses, termed TH2, is aimed at eliminating pathogens that… Read More »
Andrew Koff, PhD, Member and Professor, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center 2014 Heidi Connery Memorial Research Grant: “Proteomic and genomic approaches to understanding intrinsic and acquired resistance to CDK4 inhibition therapy in well differentiated/dedifferentiated liposarcoma” PLEASE DESCRIBE THE FOCUS OF THE RESEARCH PERFORMED IN YOUR LAB. The laboratory of cell cycle regulation at Memorial Sloan Kettering Cancer Center is interested in identifying the genes and proteins that regulate the transition of cells from quiescence, a reversible type of proliferative exit, to senescence, a more stable irreversible type of proliferative exit. Proliferation associated with a deregulated cell cycle… Read More »
M3 a market research company, is looking for people who have been diagnosed with Soft Tissue Sarcoma for an in person or webcam/telephone interview. Participants will be helping the company in the development of new treatments and to understand how to best serve patients. A short telephone conversation will confirm whether or not you qualify. You will be compensated for your time. If you live in the LA or Chicago areas, M3 would like to speak with you in person. If you are outside of these areas, it will be a webcam/telephone interview. If you are interested in participating, please contact… Read More »
DAMASCUS, Md. – May 24, 2017 – The Sarcoma Foundation of America (SFA), an organization dedicated to increased awareness and research for sarcoma, today announced that it has awarded $500,000 in research funds to deserving scientists at institutions across the United States as part of its 2017 SFA Research Grant program. Ten research grants, each worth $50,000, have been awarded to researchers who have made it their mission to study sarcoma, a rare cancer that arises in the body’s soft tissue and bone. All proposals are peer reviewed by members of the SFA Medical Advisory Board who award the… Read More »
– Vision of Hope Award to be presented at the SFA’s 15th Annual Fundraising Gala – DAMASCUS, Md. – April 10, 2017– The Sarcoma Foundation of America (SFA), an organization dedicated to increased research funding and advocacy for sarcoma, is pleased to announce that Lilly Oncology is the 2017 recipient of the Vision of Hope Award. Lilly Oncology will be honored at the SFA’s 15th Annual New York fundraising gala, “A Celebration of Life.” The event will take place on April 20, 2017, at Guastavino’s, 409 E 59th Street, New York, NY. The Vision of Hope Award is presented… Read More »
Analysis Group, Inc. (AG) is surveying individuals with Soft Tissue Sarcoma to understand their preferences for treatment of soft tissue sarcoma. Your participation will help to advance knowledge in this field. The Study: AG is seeking individuals with Soft Tissue Sarcoma to share their views and preferences for treatments of soft tissue sarcoma in an online survey lasting approximately 15-20 minutes. To Participate: You will be eligible to participate if you meet all of the eligibility criteria described below. Your participation is voluntary. You will not be asked to provide personal identifying information in this survey. Your responses… Read More »
Today’s post was written by Bert E. Thomas IV, PhD, MBA, CEO of the Sarcoma Foundation of America. Two years ago, I wrote a blog post in honor of Rare Disease Day. Entitled, “Shedding Light on the Forgotten Cancer,” it was a piece meant to raise awareness for a little known disease on a day designed to bring attention to a community of patients that are so often overlooked. It seems appropriate to share that post again as we are near Rare Disease Day 2017. On the last day of February, the rare disease community will collectively join voices and… Read More »
Today’s post was written by Bert E. Thomas IV, PhD, MBA, CEO of the Sarcoma Foundation of America. There was a long period of time where there seemed to be little to no progress in finding ways to battle the forgotten cancer known as sarcoma. This period of time lasted for decades, though it probably felt more like centuries to the patients and families that were desperately looking for treatment options that never seemed to come. And while sarcoma still takes too many of our loved ones from us, progress in our fight against this terrible disease is finally being… Read More »
-Drug Approved for Use in Treatment of Advanced Liposarcoma and Leiomyosarcoma- DAMASCUS, Md. – October 23, 2015 – The Sarcoma Foundation of America (SFA) applauds the announcement by the Food and Drug Administration (FDA) that the drug Yondelis (trabectedin, marketed by Janssen) has been approved by the agency for the treatment of advanced liposarcoma and leiomyosarcoma, two subtypes of soft tissue sarcoma. Yondelis has received approval for the use in the treatment of patients with unresectable or metastatic liposarcoma and leiomyosarcoma who have previously received an anthracycline chemotherapy. “The Sarcoma Foundation of America is thrilled with the FDA’s decision to approve… Read More »